Last product to come out of BMS lab.

Quote




Actually not sure. In CV nothing in the past 25 years. All drugs were purchased. Oncology very similar I think. With exception of opdivo. Other divisions same thing.
 




anonymous said:
Actually not sure. In CV nothing in the past 25 years. All drugs were purchased. Oncology very similar I think. With exception of opdivo. Other divisions same thing.
Click to expand...
Not even Opdivo lol. Opdivo came from a company acquisition in the late 2000s, I remember it well. This place is where innovation comes to die.
 




















You should be asking what BMS Discovery found and C-Wing gave away. BMS has paraded a steady retinue of C-Wing addled wallflowers since about the 2008, who gave away more more discoveries than they ever developed. Theres about 4 industry leading drugs, and several others in development/given away, or co-marketed that seemed like weak/awful deals jn the industry.The talent behind all of these drugs, were all gone, or treading water to retirement in about 2014 and/or definitely left after the CELG catastrophe. BMS RnD aint what it used to be.
 












anonymous said:
You should be asking what BMS Discovery found and C-Wing gave away. BMS has paraded a steady retinue of C-Wing addled wallflowers since about the 2008, who gave away more more discoveries than they ever developed. Theres about 4 industry leading drugs, and several others in development/given away, or co-marketed that seemed like weak/awful deals jn the industry.The talent behind all of these drugs, were all gone, or treading water to retirement in about 2014 and/or definitely left after the CELG catastrophe. BMS RnD aint what it used to be.
Click to expand...
This sums up eliquis in a nutshell.
 




i do not know of any meaningful product that has come out of BMS labs during this century. everything in our portfolio has been sourced from other companies through acquisitions and licensings. it is a not-so-well kept secret in the industry that we have a broken culture run by incompetent consultants (Boerner) who do not know what the heck they are doing and why.. v. similar to what is happening to Boeing right now
 








anonymous said:
i do not know of any meaningful product that has come out of BMS labs during this century. everything in our portfolio has been sourced from other companies through acquisitions and licensing. it is a not-so-well kept secret in the industry that we have a broken culture run by incompetent consultants (Boerner) who do not know what the heck they are doing and why.. v. similar to what is happening to Boeing right now
Click to expand...
There are several home grown BMS drugs on the market including Eliquis, Dapigaflizin, Nurtec, Zavspret, Baraclude, Sotyktu, Daklinza to name few. Several others are still in development and may succeed. Many antivirals, were spun out to Abbvie when BMS execs decided to leave antivirals. BMS sold substantial and valuable amount legacy inventions outright or for co-development with partners, and misfired on several BD opportunities. The current CSO likes his own ideas, disliked legacy BMS and now has a legion of loyal, yet unremarkable biotech Celgene R&D types working for him. I do not expect much from his internal division going forward.
 








anonymous said:
Eliquis came from a previous buyout.
Click to expand...
Not exactly true. I think I have this correct-While the groundwork (Dupont), led to Razaxaban, it was eclipsed by the optimized apixaban (Eliquis), from the newly combined teams. Truth is that the hard work was a combined effort of these teams and is published as such. This sort of medicinal optimization happens regularly with combined companies. (By the way, those factor XIa scientists mostly all left when the Celgene guys started their magical transformation of BMS R&D.)
 




The answer is right in front of everyone to see. If there was any real innovation going on here we would just not be looking at a $30 billion revenue cliff as Eliquis and Opdivo lose exclusivity. As far as I can see, we have nothing in the pipeline or recently launched that is going to overcome that.

Acquiring companies can only take you so far, esp. with the poor track record BMS has of doing so, and we are now at the point where that has run its course. Hence mass layoffs.

Lights out. It's over. No coming back from the mess that has been created.
 








anonymous said:
Not exactly true. I think I have this correct-While the groundwork (Dupont), led to Razaxaban, it was eclipsed by the optimized apixaban (Eliquis), from the newly combined teams. Truth is that the hard work was a combined effort of these teams and is published as such. This sort of medicinal optimization happens regularly with combined companies. (By the way, those factor XIa scientists mostly all left when the Celgene guys started their magical transformation of BMS R&D.)
Click to expand...
The Celgene transformation included selling off valuable and easier to use BMS pipeline drugs because of heavy self interest on Celgene’s part. BMS leadership is to blame for allowing grave mistakes to happen so that Celgene people could sustain themselves. The mistakes included placing Celgene people as heads of multiple functions and kissing up to them, allowing them to trash and mock BMS people and BMS drugs in clinical trials and the approved drugs that were showing improved results. Celgene people have also found their ways in business development at BMS. They are everywhere with multiple promotions. Promoting too many and too fast all over the place was a big mistake. However, that does not excuse the incompetence on the part of BMS or rather retaining the incompetent and laying off the worthy.
 




anonymous said:
The Celgene transformation included selling off valuable and easier to use BMS pipeline drugs because of heavy self interest on Celgene’s part. BMS leadership is to blame for allowing grave mistakes to happen so that Celgene people could sustain themselves. The mistakes included placing Celgene people as heads of multiple functions and kissing up to them, allowing them to trash and mock BMS people and BMS drugs in clinical trials and the approved drugs that were showing improved results. Celgene people have also found their ways in business development at BMS. They are everywhere with multiple promotions. Promoting too many and too fast all over the place was a big mistake. However, that does not excuse the incompetence on the part of BMS or rather retaining the incompetent and laying off the worthy.
Click to expand...
Amen!
 




Top Bottom
Back
Quote